These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 8730465)

  • 1. Soluble ELAM-1 is elevated with the progression of IgA nephropathy but not with that of polycystic kidney disease.
    Hotta O; Taguma Y; Yusa N; Kitamura H; Sudo K; Horigome I
    Nephron; 1996; 72(4):736-8. PubMed ID: 8730465
    [No Abstract]   [Full Text] [Related]  

  • 2. Serum levels of soluble Fas and disease activity in patients with IgA nephropathy.
    Shou I; Tashiro K; Kurusu A; Kaneko S; Hayashi T; Fukui M; Shirato I; Kubota K; Tomino Y
    Nephron; 1999; 81(4):387-92. PubMed ID: 10095173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone-reactive IgA antibodies in adult IgA nephropathy and other primary glomerulonephritis.
    Monestier M; Fasy TM; Novick KE; Losman MJ; Rigal D; Wong GY; Terzidis-Trabelsi H; Pilatte Y; Rostoker G
    Nephron; 1994; 68(1):25-31. PubMed ID: 7527503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum soluble interleukin 2 receptor in patients with IgA nephropathy.
    Yorioka N; Hirabayashi A; Takemasa A; Kanahara K; Takahashi N; Oda H; Joarder ZH; Harada S; Yamakido M
    Hiroshima J Med Sci; 1989 Dec; 38(4):169-71. PubMed ID: 2637244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VCAM-1, ICAM-1, and E-selectin in IgA nephropathy and Schönlein-Henoch syndrome: differences between tissue expression and serum concentration.
    Mrowka C; Heintz B; Sieberth HG
    Nephron; 1999; 81(3):256-63. PubMed ID: 10050078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced IgA nephropathy: to treat or not to treat?
    Locatelli F; Pozzi M; Del Vecchio L; Pozzi C
    Nephron Clin Pract; 2003; 93(4):c119-21. PubMed ID: 12759578
    [No Abstract]   [Full Text] [Related]  

  • 7. IgA nephropathy: a disease in search of a large-scale clinical trial to reliably inform practice.
    Strippoli GF; Maione A; Schena FP; Tognoni G; Craig JC
    Am J Kidney Dis; 2009 Jan; 53(1):5-8. PubMed ID: 19101396
    [No Abstract]   [Full Text] [Related]  

  • 8. Association of IgA nephropathy, hypothyroidism and hypercholesterolemia.
    Deák G; Ruzicska E; Somogyi A
    J Nephrol; 2005; 18(6):773-6. PubMed ID: 16358238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short-term controlled trial of cyclosporine A in IgA nephropathy.
    Lai KN; Mac-Moune Lai F; Vallance-Owen J
    Transplant Proc; 1988 Jun; 20(3 Suppl 4):297-303. PubMed ID: 3381287
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating leukocyte-endothelial adhesion molecules in IgA nephropathy.
    Lai KN; Wong KC; Li PK; Lai CK; Chan CH; Lui SF; Chui YL; Haskard DO
    Nephron; 1994; 68(3):294-300. PubMed ID: 7530811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precise ultrastructural localization of endothelial leukocyte adhesion molecule-1, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in patients with IgA nephropathy.
    Ogawa T; Yorioka N; Ito T; Ogata S; Kumagai J; Kawanishi H; Yamakido M
    Nephron; 1997; 75(1):54-64. PubMed ID: 9031271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valsartan combined with clopidogrel and/or leflunomide for the treatment of progressive immunoglobulin A nephropathy.
    Cheng G; Liu D; Margetts P; Liu L; Zhao Z; Liu Z; Tang L; Fang Y; Li H; Guo Y; Chen F; Liu F
    Nephrology (Carlton); 2015 Feb; 20(2):77-84. PubMed ID: 25358874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Progression in IgA Nephropathy in Childhood.
    Mizerska-Wasiak M; Małdyk J; Turczyn A; Cichoń-Kawa K; Rybi-Szumińska A; Wasilewska A; Bieniaś B; Zajączkowska M; Miklaszewska M; Pietrzyk J; Demkow U; Roszkowska-Blaim M; Pańczyk-Tomaszewska M
    Adv Exp Med Biol; 2017; 955():65-73. PubMed ID: 27718216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of dilazep dihydrochloride on plasma P-selectin concentrations in patients with IgA nephropathy.
    Ebihara I; Nakamura T; Suzuki S; Ushiyama C; Shimada N; Suzaki M; Koide H
    Nephron; 2000 Jul; 85(3):281-2. PubMed ID: 10867547
    [No Abstract]   [Full Text] [Related]  

  • 15. Tubulointerstitial changes are less important in membranoproliferative glomerulonephritis than in IgA nephropathy.
    Soma J; Ootaka T; Sato H; Ito S; Saito T
    Nephron; 2000 Oct; 86(2):230-1. PubMed ID: 11015015
    [No Abstract]   [Full Text] [Related]  

  • 16. [Surprising increase of creatinine].
    Schobel HP
    MMW Fortschr Med; 2013 Dec; 155(21-22):48-9. PubMed ID: 24724274
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum secretory IgA and IgM and free secretory component in IgA nephropathy.
    Mole CM; Renoult E; Béné MC; Seillès E; Kessler M; Revillard JP; Faure GC
    Nephron; 1995; 71(1):75-8. PubMed ID: 8538852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum under-galactosylated IgA1 is increased in Japanese patients with IgA nephropathy.
    Shimozato S; Hiki Y; Odani H; Takahashi K; Yamamoto K; Sugiyama S
    Nephrol Dial Transplant; 2008 Jun; 23(6):1931-9. PubMed ID: 18178603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating CD89-IgA complex does not predict deterioration of kidney function in Korean patients with IgA nephropathy.
    Jhee JH; Kang HY; Wu M; Nam BY; Chang TI; Jung SY; Park S; Kim H; Yun HR; Kee YK; Yoon CY; Park JT; Yoo TH; Kang SW; Han SH
    Clin Chem Lab Med; 2017 Nov; 56(1):75-85. PubMed ID: 28672768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgA nephropathy and polycystic kidney disease.
    Panisello JM; Martinez-Vea A; Garcia C; Carrera M; Oliver JA; Richart C
    Am J Nephrol; 1988; 8(6):477-8. PubMed ID: 3218662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.